What's new? Log in Free sign up

Transcript search / cancer vaccines

1,032 transcripts

Earnings call transcript

go to Slide 3, which has our portfolio site. Key developments in '22 were the progress of HPV positive cancer drug HB-200 in a Phase 2 single arm

Earnings call transcript

of these biologics will function as therapeutic vaccines against a broad range of tumors. Successful development of therapeutic cancer vaccines were widely

Earnings call transcript

for personalized cancer vaccines. The prospect of opening up most common solid tumors to the survival benefits of immunotherapy lies immediately ahead

Earnings call transcript

naturally be expected to include supporting clinical data from the Phase one study of Act two conducted by Cancer Research U.K. We currently are still

Earnings call transcript

with Interferon and one in combination with Vaccitech's therapeutic vaccine, VTP-300. At the end of 2022, we completed enrolment and announced preliminary data

Earnings call transcript

infectious disease portfolio. Last month, we announced positive results from a Phase 1b clinical trial evaluating INO-4201 as a booster vaccine candidate

Earnings call transcript

, right? Biologics is another modality, and that's drugs like insulin or antibody therapies for cancer. Then you have RNA therapeutics like the COVID

Earnings call transcript

moving to Slide 10, and Zepzelca. We have rapidly established Zepzelca as the treatment of choice in second-line small-cell lung cancer, achieving

Earnings call transcript

clinical trial success, and that's an engine to power personalized cancer vaccine development, as evidenced by our recent announcement of the extension

Earnings call transcript

, but it's ultimately intended for cancer prevention. Very much like the human papillomavirus HPV vaccines that protect against cervical cancer. EBV

Earnings call transcript

technology has been very useful for large companies involved in specialized, personalized cancer vaccines and enables people to make personalized

Earnings call transcript

in the Phase 3 trial. In oncology, our personalized cancer vaccine was the first demonstration of positive results from an mRNA cancer treatment

Earnings call transcript

and a lower overall contribution from vaccine-related studies. Additionally, COVID-related programs are expected to represent approximately 4% of our

Earnings call transcript

and vaccines or direct therapeutic applications. And as the heat map on the right-hand side here shows you the top disease target of these programs is cancer

Earnings call transcript

Kettering Cancer Center on the platform. Also of note, during the fourth quarter, we entered into an exclusive licensing agreement with NuProbe

Earnings call transcript

Labcorp Plasma Focus. This test is used to match cancer patients with FDA-approved therapies using the patient's circulating tumor DNA taken from

Earnings call transcript

of certain cancers. And of course, DNA itself can be used as a direct therapeutic agent in the form of DNA vaccines targeting a wide range of indications from

Earnings call transcript

of the Scientific Advisory Board of QIAGEN. As many of you may know, Rick is an American immunologist, who is an expert in vaccine, drugs and diagnostic development

Earnings call transcript

. Additionally, we received FDA approval for Libtayo in combination with chemotherapy as a first line treatment for advanced non-small cell lung cancer

Earnings call transcript

/HER2-negative metastatic breast cancer. We also expect to hear from European regulators later this year. In the meantime Trodelvy commercial momentum

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.